vs
Side-by-side financial comparison of Karyopharm Therapeutics Inc. (KPTI) and STEM, INC. (STEM). Click either name above to swap in a different company.
STEM, INC. is the larger business by last-quarter revenue ($47.1M vs $34.1M, roughly 1.4× Karyopharm Therapeutics Inc.). STEM, INC. runs the higher net margin — -33.9% vs -299.9%, a 266.0% gap on every dollar of revenue. On growth, Karyopharm Therapeutics Inc. posted the faster year-over-year revenue change (11.6% vs -15.6%). Over the past eight quarters, STEM, INC.'s revenue compounded faster (36.1% CAGR vs 1.4%).
StemCells, Inc. is a public biopharmaceutical company headquartered in Newark, California, that is developing purified human neural stem cells (HuCNS-SCs) in the hopes of treating central nervous system disorders and paralysis. StemCells' HuCNS-SCs have the ability to differentiate into the three main types of cells found in the central nervous system: neurons, astrocytes and oligodendrocytes.
KPTI vs STEM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $34.1M | $47.1M |
| Net Profit | $-102.2M | $-16.0M |
| Gross Margin | — | 48.9% |
| Operating Margin | -52.4% | -17.7% |
| Net Margin | -299.9% | -33.9% |
| Revenue YoY | 11.6% | -15.6% |
| Net Profit YoY | -232.0% | 68.8% |
| EPS (diluted) | $-7.02 | $-4.40 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $34.1M | $47.1M | ||
| Q3 25 | $44.0M | $38.2M | ||
| Q2 25 | $37.9M | $38.4M | ||
| Q1 25 | $30.0M | $32.5M | ||
| Q4 24 | $30.5M | $55.8M | ||
| Q3 24 | $38.8M | $29.3M | ||
| Q2 24 | $42.8M | $34.0M | ||
| Q1 24 | $33.1M | $25.5M |
| Q4 25 | $-102.2M | $-16.0M | ||
| Q3 25 | $-33.1M | $-23.8M | ||
| Q2 25 | $-37.3M | $202.5M | ||
| Q1 25 | $-23.5M | $-25.0M | ||
| Q4 24 | $-30.8M | $-51.1M | ||
| Q3 24 | $-32.1M | $-148.3M | ||
| Q2 24 | $23.8M | $-582.3M | ||
| Q1 24 | $-37.4M | $-72.3M |
| Q4 25 | — | 48.9% | ||
| Q3 25 | — | 35.5% | ||
| Q2 25 | — | 33.4% | ||
| Q1 25 | — | 32.4% | ||
| Q4 24 | — | -4.4% | ||
| Q3 24 | — | 21.2% | ||
| Q2 24 | — | 27.6% | ||
| Q1 24 | — | -95.0% |
| Q4 25 | -52.4% | -17.7% | ||
| Q3 25 | -34.6% | -33.6% | ||
| Q2 25 | -64.3% | -34.8% | ||
| Q1 25 | -110.8% | -65.0% | ||
| Q4 24 | -102.4% | -84.4% | ||
| Q3 24 | -67.8% | -493.2% | ||
| Q2 24 | -65.7% | -1705.5% | ||
| Q1 24 | -101.9% | -267.0% |
| Q4 25 | -299.9% | -33.9% | ||
| Q3 25 | -75.2% | -62.2% | ||
| Q2 25 | -98.2% | 527.8% | ||
| Q1 25 | -78.2% | -76.9% | ||
| Q4 24 | -100.8% | -91.6% | ||
| Q3 24 | -82.7% | -506.3% | ||
| Q2 24 | 55.6% | -1712.6% | ||
| Q1 24 | -112.8% | -283.9% |
| Q4 25 | $-7.02 | $-4.40 | ||
| Q3 25 | $-3.82 | $-2.84 | ||
| Q2 25 | $-4.32 | $-1.79 | ||
| Q1 25 | $-2.77 | $-0.15 | ||
| Q4 24 | $-2.33 | $-15.29 | ||
| Q3 24 | $-3.85 | $-18.24 | ||
| Q2 24 | $-2.97 | $-71.81 | ||
| Q1 24 | $-4.85 | $-0.46 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $60.5M | $48.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-292.9M | $-249.4M |
| Total Assets | $108.4M | $308.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $60.5M | $48.9M | ||
| Q3 25 | $37.7M | $43.1M | ||
| Q2 25 | $38.7M | $40.8M | ||
| Q1 25 | $38.8M | $58.6M | ||
| Q4 24 | $62.5M | $56.3M | ||
| Q3 24 | $72.8M | $75.4M | ||
| Q2 24 | $84.8M | $89.6M | ||
| Q1 24 | $30.6M | $112.8M |
| Q4 25 | $-292.9M | $-249.4M | ||
| Q3 25 | $-269.3M | $-235.7M | ||
| Q2 25 | $-238.9M | $-214.1M | ||
| Q1 25 | $-205.9M | $-417.5M | ||
| Q4 24 | $-186.0M | $-398.4M | ||
| Q3 24 | $-159.6M | $-344.1M | ||
| Q2 24 | $-132.1M | $-203.2M | ||
| Q1 24 | $-169.0M | $371.6M |
| Q4 25 | $108.4M | $308.9M | ||
| Q3 25 | $96.2M | $362.6M | ||
| Q2 25 | $104.9M | $379.2M | ||
| Q1 25 | $127.7M | $405.1M | ||
| Q4 24 | $164.4M | $437.4M | ||
| Q3 24 | $189.5M | $537.8M | ||
| Q2 24 | $214.0M | $691.5M | ||
| Q1 24 | $204.5M | $1.3B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-11.8M | $8.2M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-11.8M | $8.2M | ||
| Q3 25 | $-5.9M | $11.4M | ||
| Q2 25 | $-18.7M | $-21.3M | ||
| Q1 25 | $-39.0M | $8.5M | ||
| Q4 24 | $-25.8M | $-14.7M | ||
| Q3 24 | $-19.5M | $-9.4M | ||
| Q2 24 | $-38.5M | $-11.9M | ||
| Q1 24 | $-43.7M | $-621.0K |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $-25.9M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $-43.9M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -84.7% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -132.6% | — |
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.2% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 0.6% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -0.11× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -1.62× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
KPTI
| Products | $32.1M | 94% |
| License And Other | $2.0M | 6% |
STEM
Segment breakdown not available.
